Forest and Nycomed to Present Results from Six Roflumilast Posters

Update: Daliresp (roflumilast) Now FDA Approved - March 1, 2011

- Data to be presented at American Thoracic Society International Conference 2010 -

NEW YORK--(BUSINESS WIRE)--May 10, 2010 - Forest Laboratories, Inc. (NYSE: FRX) and Nycomed today announced that they will present data from six roflumilast posters during the American Thoracic Society (ATS) International Conference being held in New Orleans, LA, May 14 through May 19, 2010. Roflumilast is an investigational anti-inflammatory, oral medication for the treatment of Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis in patients at risk of exacerbations. Included in the poster presentations are additional results from the 12-month and 6-month roflumilast studies previously published in The Lancet.

The scheduled times and titles of presentations are:

 

  • Roflumilast and its active metabolite inhibit LPS-induced cytokine production from human lung macrophages by a PGE2-dependent mechanism: poster (D7) available on Sunday, May 16, 8:15 am – 4:00 pm CDT, with presentation by A. Buenestado, PhD, 10:45 am – 12:30 pm
  • Efficacy of roflumilast in patients receiving concomitant treatments for chronic obstructive pulmonary disease over 12 months: poster (F72) available on Tuesday, May 18, 8:15 am – 4:00 pm CDT, with presentation by N.A. Hanania, MD, MS, 10:45 am – 12:30 pm
  • Time course and reversibility of weight decrease with roflumilast, a PDE4 inhibitor: poster (F78) available on Tuesday, May 18, 8:15 am – 4:00 pm CDT, with presentation by F.J. Martinez, MD, MS, 10:45 am – 12:30 pm
  • Effects of roflumilast, a PDE4 inhibitor, on body composition in chronic obstructive pulmonary disease: poster (B64) available on Tuesday, May 18, 8:15 am – 4:00 pm CDT, with presentation by E.F.M. Wouters, MD, PhD, 10:45 am – 12:30 pm
  • Effects of roflumilast, a PDE4 inhibitor, on glucose homeostasis in patients with treatment-naïve diabetes: poster (B62) available on Tuesday, May 18, 8:15 am – 4:00 pm CDT, with presentation by E.F.M. Wouters, MD, PhD, 10:45 am – 12:30 pm
  • Roflumilast N-oxide partially prevents the loss of ciliated human airway epithelial cells secondary to incubation with cigarette smoke extracts in vitro: poster (B68) available on Tuesday, May 18, 8:15 am – 4:00 pm CDT, with presentation by J. Milara, PhD, 10:45 am – 12:30 pm

About COPD

COPD is an under-diagnosed, progressive lung disease that is the fourth leading cause of death in the U.S. Of the six leading causes of death in the United States, COPD and diabetes mellitus are the only diseases for which the mortality rate has increased over the past 30 years, with COPD mortality almost doubling since 1970. Approximately 12 million people in the U.S. are currently diagnosed with COPD and an additional 12 million are likely to have the disease and not know it.

Symptoms of COPD include breathlessness, chronic cough and excessive production of phlegm. A significant worsening of symptoms called an exacerbation can last several weeks and may lead to hospitalization. Exacerbations are distressing and dangerous events resulting in increased patient anxiety, worsening health status, lung function decline, and increased risk of death.

About roflumilast (Daxas®)

Roflumilast is a phosphodiesterase 4 (PDE4) enzyme inhibitor that targets the underlying inflammation associated with COPD. If approved, roflumilast, a once-a-day oral tablet, will be the first in an entirely new class of treatment for COPD. Roflumilast is not a steroid.

About Nycomed

Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.

Its R&D is structured around partnerships and in-licensing is a cornerstone of the company's growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed plans to further strengthen its own position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated total sales of ‚¬3.2 billion in 2009 and an adjusted EBITDA of ‚¬1.1 billion.

For more information, visit www.nycomed.com.

About Forest Laboratories

Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people's lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest's current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more about Forest Laboratories, visit www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings.

 

Contact: Forest Laboratories, Inc.
Frank J. Murdolo
Vice President ˆ’ Investor Relations
212-224-6714
Frank.Murdolo@frx.com

 

Posted: May 2010

View comments

Hide
(web1)